NCT03986905View on ClinicalTrials.gov

The Prevention and Treatment of Nausea Associated With Motion Sickness

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

May 19, 2019

Study Completion Date

June 19, 2019

Conditions
Motion Sickness
Interventions
DRUG

Scopolamine Nasal Gel

All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.

OTHER

Placebo

placebo nasal gel + placebo patch

Trial Locations (1)

90806

Collaborative Neuroscience Network, LLC, Long Beach

All Listed Sponsors
lead

Repurposed Therapeutics, Inc.

INDUSTRY

NCT03986905 - The Prevention and Treatment of Nausea Associated With Motion Sickness | Biotech Hunter | Biotech Hunter